Objective To investigate the clinical efficacy of multi-disciplinary collaborative diagnosis and treatment for pancreatic cancer,and provide a theoretical study for the clinical treatment of pancreatic cancer.Methods 80 patients with pan-creatic cancer,according to random number table is,were divided into the experimental group and the control group,40 patients in each.In the experimental group,patients with resectable pancreatic cancer received surgical resection and adjuvant chemoradiation ,patients with unresectable pancreatic cancer received concurrent chemotherapy and supplementary medication.In the control group,patients with resectable pancreatic cancer received surgical resection,patients with unresectable pancreatic cancer received radiation therapy.The clinical efficacy of the 2 groups were observed, serum CEA, CA19-9 and CA242 level changes of the 2 groups before and after treatment were compared,adverse reactions of the 2 groups before and after treatment were compared.Re-sults In the experimental group,there had 8 cases of CR,PR 21 cases,which were significantly higher than those of the control group,there had significant difference (P<0.05),there had 8 cases of SD,PD 3 cases,which were significantly lower than those of the control group,there had statistically significant difference(P<0.05);the long-term efficacy,the study group had 23 cases of survival,17 cases of death,the survival time was (19.50 ±5.50) months,which were significantly better than those of the control group,there had significant difference (P<0.05);before treatment,serum CEA,CA19-9 and CA242 level of the 2 groups had no significant difference (P>0.05),after treatment,serum CEA,CA19-9 and CA242 level in the study group decreased sig-nificantly,there had significant difference between the 2 groups (P<0.05);after treatment,both groups had nausea,vomiting, bone marrow suppression,liver damage and other adverse reactions,there had no significant difference ( P>0.05) .Conclusion Multi-disciplinary treatment of pancreatic cancer can significantly improve the clinical short-term efficacy,prolong survival of pa-tients,and decrease serum CEA,CA19-9 and CA242 levels,it has certain safety,and should be popularized in clinical.%目的：探讨分析多学科协作诊治胰腺癌患者的临床疗效，为临床治疗胰腺癌提供临床理论研究。方法选择80例胰腺癌患者，按照随机数字表法分为实验组和对照组患者，每组患者40例。实验组内，对可切除胰腺癌患者行外科手术切除术，并且给予辅助放化疗等综合治疗，对于不可切除的的胰腺癌患者行同期放化疗，并给予辅助药物治疗。对照组患者中，对于可切除胰腺癌患者只行外科手术切，对于不可切除的的胰腺癌患者只给予单一放疗。观察两组患者的临床疗效；比较两组患者治疗前后血清CEA、CA19-9和CA242水平的变化；分析两组患者治疗前后不良反应的差异性。结果实验组患者中CR8例，PR21例，均显著多于对照组的例数，具有明显差异性（P＜0．05），SD8例，PD3例，均显著少于对照组患者的例数，具有统计学意义（P＜0．05）；在远期疗效，实验组患者生存23例，死亡17例，生存时间为（19．50±5．50）个月，均显著优于对照组患者，具有显著性差异（P＜0．05）；治疗前两组患者血清CEA、CA19-9和CA242水平比较无差异性（P＞0．05），治疗后实验组患者三项指标水平均明显降低，与对照组比较具有明显差异性（P＜0．05）；治疗后两组患者均出现恶心、呕吐、骨髓抑制以及肝功能损伤等不良反应，无差异性（ P＞0．05）。结论多学科协作诊治胰腺癌患者，能够显著提高临床近期疗效，明显延长患者的生存期限，降低血清CEA、CA19-9和CA242水平，具有一定的安全性，值得在临床上广泛推广。
展开▼
